[Federal Register Volume 79, Number 83 (Wednesday, April 30, 2014)]
[Notices]
[Pages 24439-24440]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-09766]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-14-14VP]


Proposed Data Collections Submitted for Public Comment and 
Recommendations

    In compliance with the requirement of Section 3506(c)(2)(A) of the 
Paperwork Reduction Act of 1995 for opportunity for public comment on 
proposed data collection projects, the Centers for Disease Control and 
Prevention (CDC) will publish periodic summaries of proposed projects. 
To request more information on the proposed projects or to obtain a 
copy of the data collection plans and instruments, call 404-639-7570 
and send comments to Leroy Richardson, 1600 Clifton Road, MS-D74, 
Atlanta, GA 30333 or send an email to [email protected].
    Comments are invited on: (a) Whether the proposed collection of 
information is necessary for the proper performance of the functions of 
the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (d) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques or other 
forms of information technology. Written comments should be received 
within 60 days of this notice.

Proposed Project

    Community Context Matters Study--New--National Center for HIV/AIDS, 
Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease 
Control and Prevention (CDC).

Background and Brief Description

    The daily use of specific antiretroviral medications by persons 
without human immunodeficiency virus (HIV) infection, but at high risk 
of sexual or injection exposure to HIV has been shown to be a safe and 
effective HIV prevention method. The Food and Drug Administration 
approved the use of Truvada[supreg] for preexposure prophylaxis (PrEP) 
in July 2012 and CDC has issued clinical practice guidelines for its 
use. With approximately 50,000 new HIV infections each year, increasing 
rates of infection for young MSM, and continuing severe disparities in 
HIV infection among African-American men and women, incorporation of 
PrEP into HIV prevention is important. However, as a new prevention 
tool in very early stages of introduction and use, there is much we 
need to learn about how to implement PrEP in a real world setting and 
the need to develop and validate new measurement tools to capture this 
information.
    CDC is requesting Office of Management and Budget (OMB) approval to 
collect data over a three-year period that will be used to (1) assess 
the utility of new measures developed or adapted to collect information 
related to this new intervention (PrEP) and (2) evaluate community 
contextual factors that may impact the acceptability and successful 
introduction of a new HIV prevention method. The project will be 
conducted in communities in each of four cities where PrEP has recently 
become available through a local community health center.
    Once per year for three years, two surveys will be conducted: (1) A 
community-based survey to be administered to 40 persons per city 
approached in public venues in the catchment areas of the PrEP clinics, 
and (2) a key stakeholder survey to be administered to 10 community HIV 
leaders nominated by PrEP clinic staff and HIV community-based 
organizations in the clinic communities.

[[Page 24440]]

Both surveys will collect data on the demographics of the participants, 
knowledge of PrEP, misinformation about PrEP, and attitudes about it. 
The neighborhood survey will also include questions about basic HIV 
knowledge, attitudes, and beliefs as well as information about sexual 
and drug use behaviors that are indications for PrEP use. For the 
stakeholder survey, additional questions will be included about type of 
organization where they work and organizational experience with PrEP.
    Surveys will be administered face-to-face by trained, local 
interviewers.
    There are no costs to respondents other than their time.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                     Number of
      Type of respondent            Form name        Number of     responses per   Average hours  Total response
                                                    respondents     respondent     per response   burden (hours)
----------------------------------------------------------------------------------------------------------------
Neighborhood Survey Street      Neighborhood                 720               1            5/60              60
 Interview Participant.          Interview
                                 Recruitment
                                 Script and
                                 Informed
                                 Consent.
Key Stakeholder Participant...  Key Stakeholder              180               1            5/60              15
                                 Telephone
                                 Recruitment
                                 Script and
                                 Informed
                                 consent.
Street Interview Participant..  Survey..........             480               1           20/60             160
Key Stakeholder Participant...  Survey..........             120               1           20/60              40
                                                 ---------------------------------------------------------------
    Total.....................  ................  ..............  ..............  ..............             275
----------------------------------------------------------------------------------------------------------------


LeRoy Richardson,
Chief, Information Collection Review Office, Office of Scientific 
Integrity, Office of the Associate Director for Science, Office of the 
Director, Centers for Disease Control and Prevention.
[FR Doc. 2014-09766 Filed 4-29-14; 8:45 am]
BILLING CODE 4163-18-P